Also, Cagrisema, their drug in Phase 2 development, achieved 22.7% of weight loss in patients part of the 68-week REDEFINE 1 study. In REDEFINE 2, patients lost 15.1% of weight in the same time ...

Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight ...

United Biotechnology will get $200M upfront, up to $1.8B in milestones, and royalties as part of its UBT251 licensing deal with Novo Nordisk A phase 1b trial of UBT251 showed a 15.1% weight loss ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that Novo's next-generation CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15. ...